Uses and Benefits of Skyla

Skyla is a progestin-containing intrauterine system (IUS) indicated for the prevention of pregnancy for up to three years. It is a highly effective, continuous, and long-term method of reversible contraception.

---

Main Uses

Skyla's primary authorized use is to prevent pregnancy in women of childbearing age, including those who have not given birth. It is inserted into the uterus by a healthcare provider.

Benefits of Treatment

One primary benefit is the method's high level of effectiveness in preventing unintended pregnancy. The device works continuously without the need for daily dosing or action, offering a convenient, long-term solution. The system contains levonorgestrel, a synthetic progestin hormone, which is released locally within the uterus. The contraceptive reliability lasts for a period of up to three years, after which the system must be removed or replaced.

Skyla can be removed by a healthcare provider at any time if a patient chooses to stop use. Upon removal, fertility returns promptly, allowing the patient to attempt to conceive immediately.

Eligibility Scope

Skyla is officially indicated for use in women of childbearing age for the prevention of pregnancy, which includes adolescents and women who have not previously given birth. However, official regulatory labeling establishes definitive rules for who must not use the medicine.

Absolute Contraindications

Use is absolutely prohibited (contraindicated) if the patient has or is suspected to have one or more of the following conditions:

• Pregnancy or suspicion of pregnancy.
• Acute pelvic inflammatory disease (PID) or a history of PID (unless followed by a subsequent intrauterine pregnancy).
• Known or suspected breast cancer or other progestin-sensitive cancer.
• Acute liver disease or a liver tumor.
• Undiagnosed abnormal uterine bleeding or a uterine anomaly that distorts the cavity.

Age and Conditional Restrictions

Skyla is not recommended for use in the geriatric population (women over 65) as safety and efficacy in this age group have not been established by regulators. While use is allowed in adolescents, it is not recommended prior to the start of menstruation. Additionally, the risk of uterine perforation is increased if insertion occurs while the patient is breastfeeding.

Interactions with other medicines and products

The official regulatory profile for Skyla (Levonorgestrel IUS) details potential interactions based on the systemic metabolism of the active ingredient, Levonorgestrel (LNG). No specific drug-drug interaction studies were conducted with the intrauterine system itself.

Category	Officially Documented Interaction Pattern
Exposure Modification	Co-administration with enzyme-modulating agents may alter systemic LNG serum concentrations.
Mechanistic Basis	Pharmacokinetic interaction involving the induction or inhibition of LNG-metabolizing enzymes, predominantly CYP3A4.

Medicinal products and substances documented as enzyme inducers (e.g., certain anticonvulsants, Rifampicin) may result in a decreased systemic serum concentration of Levonorgestrel. The profile specifically cites the herbal product St. John’s wort (Hypericum perforatum) as a substance that may reduce systemic LNG exposure via this induction mechanism. Conversely, co-administration with enzyme inhibitors is documented as potentially increasing the systemic LNG serum concentrations.

The regulatory documentation, however, provides a key constraint on the clinical significance of these systemic changes: since the primary contraceptive effect of the Levonorgestrel IUS is driven by the hormone’s continuous localized release into the uterine cavity, this local action is formally stated to be unlikely to be affected by alterations in systemic blood concentrations. The product labeling details no mandatory timing separation rules or absolute interaction-based prohibitions.

The mechanism of action is initiated by the continuous, localized release of the synthetic hormone Levonorgestrel directly into the uterine cavity. This targeted delivery results in high hormone concentrations at the reproductive tract tissues, influencing two primary biological systems.

Cervical Mucus Dynamics

Levonorgestrel acts as an agonist on progesterone receptors in the cervical mucosa, rapidly inducing a high-level thickening and reduction in the volume of the cervical mucus. The resulting physiological change transforms the mucus into a dense, non-permeable physical and chemical barrier that restricts sperm migration into the upper genital tract, which is a key prerequisite for fertilization.

Endometrial and Gamete Function Modulation

High local hormone concentration modulates the Endometrial Histological Pathway, causing changes like glandular atrophy and stromal pseudodecidualization of the uterine lining. This physiological transformation induces structural and chemical alterations in the endometrium. Simultaneously, the hormone directly interferes with sperm motility and survival within the uterine fluid. This multi-layered approach results in compounding physiological consequences that restrict key reproductive processes.

How to Use Skyla (Levonorgestrel-Releasing Intrauterine System)

Skyla is a long-acting, reversible method of contraception that is placed directly into the uterus. The entire system contains 13.5 mg of the progestin levonorgestrel. It works by continuously releasing the hormone locally, beginning at a rate of approximately 14 mcg/day after 24 days, and declining to 5 mcg/day after 3 years.

Administration and Removal

Skyla must be inserted and removed by a trained healthcare professional. This procedure is done in a healthcare setting using strict aseptic (sterile) technique.

Procedural Steps	Details
Route	Intrauterine (inserted into the uterine cavity).
Insertion Timing	May be inserted during the first seven days of the menstrual cycle, or immediately after a first-trimester abortion. If insertion occurs at any other time, use back-up contraception for the next seven days.
Duration of Use	The system provides continuous treatment for up to three years and must be removed or replaced at the end of the third year.
Follow-Up	A clinical re-examination and evaluation by the healthcare provider should occur 4 to 6 weeks after the initial insertion. Subsequent follow-up examinations should occur yearly, or more often if clinically necessary.

Important Procedural Considerations

The Skyla system is packaged within a sterile inserter; no preparation steps like dilution or shaking are required by the patient or provider. Skyla is approved for use in postpubertal females. There are no patient-controlled missed-dose rules, as the system provides a continuous release of medication over its 3-year duration.

Research Evidence / Overview of Studies for Skyla

Evidence for Use in Preventing Pregnancy

The primary evidence supporting Skyla's authorized use was collected in large-scale, multicenter clinical trials. These pivotal studies were designed as open-label, non-comparative trials; this means participants knew they were receiving the device, and observed outcomes were measured over time rather than being directly compared against another specific contraceptive brand.

Researchers focused mainly on measuring contraceptive outcomes, which was tracked by calculating the annual and cumulative pregnancy rates observed in the study populations. The studies monitored outcomes for a defined period of 3 years, the timeframe matching the approved duration of use. Secondary research also examined the rate of device loss or removal (expulsion rate) and reasons why participants chose to stop using it before the three years were complete (discontinuation rate), often related to changes in bleeding patterns.

Evidence in Special Populations

The clinical trials included both women who had previously given birth (parous) and women who had not (nulliparous or nulligravid). Research examined the data in these subgroups to ensure the findings applied across this key difference in prior parity status. Findings related to contraceptive outcomes indicated that the measured rates of pregnancy for nulliparous women were comparable to the rates reported for parous women.

However, some research focusing on the insertion process was associated with observations that nulliparous women presented greater procedural challenges and may more frequently require assistance during the insertion procedure than parous women. The research describes observations regarding the rate of insertion and post-insertion monitoring across these two groups.

Duration of Studies and Follow-up

Studies also explored what happens after the device is removed. Research examined the timing of fertility return following removal of the device by a healthcare provider. Findings described patterns observed in the studies related to the timing of the return of the ability to attempt conception following removal.

Research Limitations and Uncertainty

While large-scale clinical trials exist, long-term effects are not fully established beyond the approved defined period of study. Official research documentation and regulatory authorization are based on data collected over the defined 3-year period, and there are no published pivotal data supporting extended use.

Furthermore, comparative evidence is lacking in some areas. Because the primary trials were open-label and non-comparative, there is limited information derived from direct, randomized comparison studies of Skyla specifically against other low-dose levonorgestrel-releasing intrauterine systems or against non-hormonal IUDs. The research provides context for the observed patterns, but data for certain groups remain insufficient regarding long-term outcomes.

Key Studies & References

1. U.S. FDA Approves Bayer's Skyla™ (Levonorgestrel-Releasing Intrauterine System) 13.5 mg For Prevention Of Pregnancy For Up To Three Years (Phase 3 Trial Data)
2. Levonorgestrel-Releasing Intrauterine System as a Contraceptive Method in Nulliparous Women: A Systematic Review

Common questions about Skyla (FAQ)

---

Q: How is Skyla different from other IUDs like Mirena or Kyleena?

Official documents describe Skyla as a low-dose levonorgestrel-releasing system. It is approved for use for up to three years, which is a shorter duration than some other levonorgestrel IUS brands. The total hormone content of 13.5 mg is also lower compared to other similar devices approved for longer use periods.

---

Q: Do you get your period while using Skyla?

Bleeding patterns commonly change when using this device. Official product information indicates that irregular bleeding and spotting are very common, especially during the first few months. For many users, periods become lighter, and some individuals may find that their periods stop completely after about a year of use.

---

Q: How soon after insertion is Skyla considered effective?

According to official regulatory guidance, Skyla is considered effective immediately if the insertion occurs within the first seven days of a menstrual cycle. If the device is inserted at any other time, non-hormonal back-up contraception is used for the following seven days, as stated in the regulatory guidance.

---

Q: Is it normal to have spotting or irregular bleeding with Skyla, and how long does it last?

Yes, irregular bleeding and spotting are classified as a very common experience, especially during the first three to six months after placement. Official safety information indicates that these bleeding pattern changes are most frequent during the first year of use of the system.

---

Q: Can taking certain antibiotics make Skyla less effective?

Official regulatory profiles note that some medications, such as the antibiotic Rifampicin, can reduce the systemic levels of levonorgestrel in the bloodstream. However, the system's primary effect comes from the localized release of the hormone directly into the uterus. Because of this localized action, the contraceptive effect is generally considered unlikely to be affected by these changes in systemic blood concentration, due to its localized action.

---

Q: What is the risk of expulsion for Skyla, and what does that mean?

Expulsion refers to the device partially or completely coming out of the uterus. Clinical studies indicate this is a common, though low, risk, occurring in about 3 out of every 100 users. It is most likely to happen in the first year and results in a loss of pregnancy protection, which requires the use of back-up contraception, according to patient guidance.

---

Q: What are the warning signs that Skyla might be causing a serious problem?

Regulatory documents list several serious but rare risks that are described as potentially serious and warrant consultation with a healthcare provider. Warning signs include severe lower abdominal or pelvic pain, which may indicate issues like ectopic pregnancy or Pelvic Inflammatory Disease (PID). Other concerning signs include unexplained fever, chills, unusually heavy or prolonged bleeding, and yellowing of the skin or eyes (jaundice).

---

Q: Can a person get pregnant immediately after Skyla is removed?

Yes, a person may become pregnant immediately after the device is removed by a healthcare provider. Research examining fertility return found that a large percentage of women who desired pregnancy were able to conceive within one year after the removal procedure.

---

Q: What should I do if my period stops completely while using Skyla?

The official patient information states that if your menstrual period stops completely (amenorrhea) and you are concerned about pregnancy, official patient information advises taking a pregnancy test if you have concerns about pregnancy. It is also noted that contacting a healthcare provider may be warranted if you have not had a period for six weeks.

---

Q: Does taking Skyla change when I ovulate?

Official regulatory documents indicate that the primary way Skyla prevents pregnancy is through localized actions in the uterus, such as thickening the cervical mucus and altering the uterine lining. While some systemic hormone is present, effects on the release of an egg (ovulation) may vary and are considered a secondary and variable part of the mechanism for this low-dose system.

---

Q: Does having Skyla inserted hurt, and what can be done for pain?

During and immediately after the insertion procedure, it is common to experience pain, bleeding, and potentially dizziness. Official regulatory guidance suggests consulting a healthcare provider if symptoms persist beyond 30 minutes.

---

Q: What is the difference between Skyla and the copper IUD?

Skyla is a hormonal device that uses continuous, localized release of the synthetic hormone levonorgestrel to prevent pregnancy. This mechanism involves thickening the cervical mucus and modifying the uterine lining. In contrast, the copper IUD is a non-hormonal device that relies on the effect of copper to prevent conception.

---

Q: Can certain medical tests, like an MRI, affect Skyla?

The device is classified as 'MR Conditional' in official safety information. This means a patient with Skyla can be safely scanned under certain conditions, specifically in an MRI system with a static magnetic field of 3.0 T or less. The official documentation includes a recommendation that patients inform both their healthcare provider and the MRI staff that they have the device prior to the procedure.

---

Q: Can Skyla be used to treat heavy periods, or is it only for birth control?

According to its official regulatory indications, Skyla is approved solely for the prevention of pregnancy (contraception) for up to three years. It is not approved or formally indicated for the therapeutic treatment of conditions such as heavy menstrual bleeding.

---

Q: Does Skyla cause weight gain for most people?

Based on clinical study data summarized in the official product labeling, weight gain is not listed as a very common or common side effect. Changes in body weight were documented as an uncommon adverse reaction, meaning it affected less than 1 in 100 users.

---

Q: Does Skyla's effectiveness decrease over time?

The amount of levonorgestrel released by the system does decline over its three-year duration. However, the pivotal clinical trials confirmed the high level of effectiveness for pregnancy prevention throughout the entire three-year period, which is the basis for its approved duration of use.

---

Q: Is it possible for the strings of Skyla to go missing?

Yes, official patient information advises that if you are unable to feel the removal threads (strings) when checking for them, the device may have moved from its correct position or may have been expelled. If this happens, back-up contraception is used, and consultation with a healthcare provider for follow-up evaluation is warranted.

---

Q: Can I use tampons or a menstrual cup while I have Skyla?

The official patient instructions state that both tampons and menstrual cups may be used while the device is in place. The instructions advise careful removal to minimize the risk of accidentally pulling on the removal threads of the device.

---

Q: Does Skyla protect against sexually transmitted infections (STIs)?

Official regulatory documents clearly state that Skyla is a contraceptive device and does not protect against Human Immunodeficiency Virus (HIV) infection (AIDS) or any other sexually transmitted infections (STIs).

---

Q: Can I feel the Skyla inside me during daily activities?

The device is located within the uterus, and generally, neither the user nor their partner should be able to feel the plastic T-shaped frame during daily activities or sexual intercourse. However, official information notes that a partner might occasionally feel the soft removal threads.

---

Q: Can Skyla be used for emergency contraception?

Skyla is approved for long-acting, reversible contraception for a continuous period of up to three years. Official regulatory information specifies that it is not approved or indicated for use as a form of emergency contraception.

---

Q: Why is Skyla only recommended for a shorter period than Mirena?

The approved duration of use for Skyla is based on the supporting clinical evidence. The pivotal clinical studies used to confirm the device's high effectiveness tracked outcomes for a defined period of three years, which is the basis for its regulatory authorization.

---

Q: Is Skyla available in generic form?

Skyla is a brand-name prescription product. As of the official regulatory information, there is currently no FDA-approved generic version of the levonorgestrel 13.5 mg intrauterine system available in the United States.

The official storage and disposal guidelines for Skyla (levonorgestrel-releasing intrauterine system) focus on maintaining the device's sterility before use and defining its proper removal.

Storage Requirements

• Temperature and Safety: Store the unopened, packaged system at room temperature.
• Child Safety: Like all medical devices and medications, the packaged system must be kept out of the reach of children and pets.
• Packaging Integrity: The device is supplied in a sterile package. Do not open the package until the time of insertion, and do not use the device if the seal is broken or compromised, as this risks loss of sterility.

Handling and Disposal

• Aseptic Handling: The insertion procedure must be performed by a healthcare professional using strict aseptic technique.
• Device Removal: Skyla is approved for continuous use for up to 3 years. Following this period, or if removal is medically necessary, the device must be removed or replaced by a healthcare provider.